SAFETY DATA SHEET

Timolol / Dorzolamide Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Timolol / Dorzolamide Formulation

Manufacturer or supplier’s details

Company: MSD
Address: Avenida Tanner de Melo, Quadra 10 Lote 4A, Galpão A
Parque Industrial Vice Presidente José Alencar Aparecida de
Goias – GO, Brazil
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Specific target organ toxicity - repeated exposure: Category 1 (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs)

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms: 

Signal Word: Danger

Hazard Statements: H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Precautionary Statements: Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:
P314 Get medical advice/ attention if you feel unwell.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS
SAFETY DATA SHEET

Timolol / Dorzolamide Formulation

Version: 6.1
Revision Date: 16.10.2020
SDS Number: 28795-00017
Date of last issue: 23.03.2020
Date of first issue: 06.11.2014

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dorzolamide</td>
<td>130693-82-2</td>
<td>Acute toxicity (Oral), Category 4, Specific target organ toxicity - repeated exposure (Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder), Category 2</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
<tr>
<td>(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate</td>
<td>26921-17-5</td>
<td>Acute toxicity (Oral), Category 4, Reproductive toxicity, Category 2, Specific target organ toxicity - repeated exposure (Lungs, Cardio-vascular system), Category 1</td>
<td>&gt;= 0.1 - &lt; 1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES
SAFETY DATA SHEET
Timolol / Dorzolamide Formulation

Version 6.1  Revision Date: 16.10.2020  SDS Number: 28795-00017  Date of last issue: 23.03.2020
Date of first issue: 06.11.2014

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)
Sulfur oxides
Hydrogen chloride

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe mist or vapors.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dorzolamide</td>
<td>130693-82-2</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-</td>
<td>26921-17-5</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>morpholino-1,2,5-thiadiazole monomaleate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Eye, Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**: Particulates type

**Hand protection**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance**: liquid
- **Color**: colorless
- **Odor**: No data available
- **Odor Threshold**: No data available
- **pH**: 5.6
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper**: No data available
SAFETY DATA SHEET

Timolol / Dorzolamide Formulation

flammability limit

Lower explosion limit / Lower flammability limit: No data available

Vapor pressure: No data available

Relative vapor density: No data available

Relative density: 1.02

Density: No data available

Solubility(ies)

Water solubility: soluble

Partition coefficient: n-octanol/water: No data available

Autoignition temperature: No data available

Decomposition temperature: No data available

Viscosity

Viscosity, kinematic: No data available

Explosive properties: Not explosive

Oxidizing properties: The substance or mixture is not classified as oxidizing.

Molecular weight: No data available

Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.

Chemical stability: Stable under normal conditions.

Possibility of hazardous reactions: Can react with strong oxidizing agents.

Conditions to avoid: None known.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure: Inhalation

Skin contact

Ingestion

Eye contact

Acute toxicity

Not classified based on available information.
Product:
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:
Dorzolamide:
Acute oral toxicity: LD50 (Rat): 1.927 mg/kg
LD50 (Mouse): 1.320 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Acute oral toxicity: LD50 (Rat): 1.000 mg/kg
LD50 (Mouse): 1.140 mg/kg
Acute toxicity (other routes of administration):
Application Route: Intraperitoneal
LD50 (Mouse): 300 mg/kg
Application Route: Subcutaneous
LD50 (Mouse): 800 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Dorzolamide:
Species: Monkey
Result: Mild eye irritation

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species: Rabbit
Result: Mild eye irritation

Species: Dog
Result: No eye irritation
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Dorzolamide:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Routes of exposure</th>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximization Test</td>
<td>Skin contact</td>
<td>Guinea pig</td>
<td>Weak sensitizer</td>
</tr>
</tbody>
</table>

Germ cell mutagenicity
Not classified based on available information.

Components:

Dorzolamide:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromosomal aberration</td>
<td>Chromosomal aberration test</td>
<td>negative</td>
</tr>
<tr>
<td>Alkaline elution assay</td>
<td>Alkaline elution assay test system: rat hepatocytes</td>
<td>negative</td>
</tr>
<tr>
<td>In vitro mammalian cell gene mutation test</td>
<td>In vitro mammalian cell gene mutation test system: Chinese hamster fibroblasts</td>
<td>negative</td>
</tr>
<tr>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>Bacterial reverse mutation assay (AMES) system: mouse</td>
<td>negative</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo:

<table>
<thead>
<tr>
<th>Species</th>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>OECD Test Guideline 474</td>
<td>negative</td>
</tr>
</tbody>
</table>

(S)-3-[3-(tert-buty lamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type</th>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>Bacterial reverse mutation assay (AMES)</td>
<td>OECD Test Guideline 471</td>
<td>negative</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo:

<table>
<thead>
<tr>
<th>Species</th>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>OECD Test Guideline 474</td>
<td>negative</td>
</tr>
</tbody>
</table>

Carcinogenicity
Not classified based on available information.
SAFETY DATA SHEET

Timolol / Dorzolamide Formulation

Components:

Dorzolamide:
Species: Rat, male
Application Route: Oral
Exposure time: 2 Years
Result: negative
Remarks: The mechanism or mode of action may not be relevant in humans.

Species: Mouse
Application Route: Oral
Exposure time: 21 month(s)
Result: negative

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species: Rat
Application Route: Oral
Exposure time: 2 Years
LOAEL: 300 mg/kg body weight
Result: negative
Target Organs: Adrenal gland
Remarks: The significance of these findings for humans is not certain.

Species: Mouse, female
Application Route: Oral
Exposure time: 18 Months
LOAEL: 500 mg/kg body weight
Result: negative
Target Organs: Lungs, Mammary gland, Uterus (including cervix)
Remarks: The significance of these findings for humans is not certain.

Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Dorzolamide:
Effects on fertility: Test Type: Fertility
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 7.5 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development: Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight  
Early Embryonic Development: NOAEL F1: 150 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit  
Developmental Toxicity: LOAEL F1: 50 mg/kg body weight  
Result: Some evidence of adverse effects on development, based on animal experiments.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure  
Not classified based on available information.

STOT-repeated exposure  
Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Product:  
Target Organs : Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs  
Assessment : Causes damage to organs through prolonged or repeated exposure.

Components:  
Dorzolamide:  
Target Organs : Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder  
Assessment : May cause damage to organs through prolonged or repeated exposure.

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:  
Target Organs : Lungs, Cardio-vascular system  
Assessment : Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

Components:

Dorzolamide:
Species: Rat
NOAEL: 0.05 mg/kg
Application Route: Oral
Target Organs: Bladder, Kidney

Species: Dog
NOAEL: 0.05 mg/kg
LOAEL: 2 mg/kg
Application Route: Oral
Exposure time: 1 y
Target Organs: Gastrointestinal tract, Bone, Blood

Species: Monkey
NOAEL: 0.05 mg/kg
Exposure time: 1 y
Target Organs: Gastrointestinal tract, Bone, Blood

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species: Rat
NOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 67 Weeks

Species: Dog
NOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 54 Weeks
Target Organs: Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Product:
Eye contact: Symptoms: The most common side effects are: bitter taste, burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hypertension, Nausea, upper respiratory tract infection

Components:

Dorzolamide:
Eye contact: Symptoms: burning or stinging of the eye, Blurred vision, tearing, asthenia, bitter taste, Nausea, dry mouth, Headache

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Eye contact: Symptoms: burning or stinging of the eye, dryness of the eyes, Headache, Nausea, Dizziness, dry mouth, changes in libido, hair loss, Allergic reactions
Ingestion: Symptoms: Headache, Fatigue, Respiratory disorders, Gastrointestinal discomfort, Allergic reactions, Rash, hair loss, altered mental status, Dizziness, changes in libido

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Dorzolamide:**
- Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 699 mg/l
  Exposure time: 48 h
- Toxicity to microorganisms: EC50 (Natural microorganism): > 800 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition
  Method: OECD Test Guideline 209

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
- Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 411 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 161 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202
- Toxicity to microorganisms: EC50: > 1.000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

  EC50 (Photobacterium phosphoreum): > 1.800 mg/l

Persistence and degradability

**Components:**

**Dorzolamide:**
- Biodegradability: Result: not rapidly degradable
  Biodegradation: 5 %
  Exposure time: 28 d
  Method: OECD Test Guideline 314

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
- Biodegradability: Result: Not readily biodegradable.
  Biodegradation: 0 %
  Exposure time: 30 d
- Stability in water: Hydrolysis: 0 % (61 d)
  Method: FDA 3.09
Bioaccumulative potential

Components:

Dorzolamide:
Partition coefficient: n-octanol/water : log Pow: 0.292

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Partition coefficient: n-octanol/water : log Pow: 1.48

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

ANTT
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable
Brazil. List of chemicals controlled by the Federal Police : Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information


Full text of other abbreviations

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8